Article Sidebar

PDF
Issue: Vol. 563 No. 3 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v563i3.19113
Date Published: 08/10/2026
Views 0
Downloads 0
How to Cite
Hoàng, T. V., Trịnh, L. H., & Phạm, T. A. (2026). TREATMENT OUTCOMES OF PEMBROLIZUMAB PLUS CHEMOTHERAPY IN RECURRENT/METASTATIC NON-SMALL CELL LUNG CANCER AT HANOI MEDICAL UNIVERSITY HOSPITAL. Vietnam Medical Journal, 563(3). https://doi.org/10.51298/vmj.v563i3.19113

TREATMENT OUTCOMES OF PEMBROLIZUMAB PLUS CHEMOTHERAPY IN RECURRENT/METASTATIC NON-SMALL CELL LUNG CANCER AT HANOI MEDICAL UNIVERSITY HOSPITAL

Thanh Việt Hoàng1, , Lê Huy Trịnh2, Tuấn Anh Phạm3
1 Trường Đại học Y Hà Nội
2 Bộ môn Ung thư, Trường Đại học Y Hà Nội
3 Bệnh viện K

Main Article Content

Abstract

Objective: To evaluate the treatment outcomes of pembrolizumab plus chemotherapy in patients with recurrent/metastatic non-small cell lung cancer (NSCLC).


Methods: A total of 40 patients with recurrent/metastatic NSCLC treated with pembrolizumab plus chemotherapy at Hanoi Medical University Hospital from January 2020 to January 2026 were included.


Results: The overall response rate was 57.5%, with a disease control rate of 90%. Median progression-free survival was 10 months (95% CI: 4.88–15.12). Common adverse events included anemia (55%), neutropenia (35%), vomiting (27.5%), and elevated liver enzymes (22.5%), mostly grade 1–2. Immune-related adverse events included interstitial pneumonitis (5%) and hepatitis (5%).


Conclusion: Pembrolizumab plus chemotherapy showed promising efficacy and acceptable toxicity in recurrent/metastatic NSCLC.

Keywords

Non-small cell lung cancer (NSCLC), immunotherapy, pembrolizumab plus chemotherapy

Article Details

References

1. Sung, H. et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin 76, e70090 (2026).
2. Blank, C. & Mackensen, A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56, 739–745 (2007).
3. Novello, S. et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol 41, 1999–2006 (2023).
4. Garassino, M. C. et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 41, 1992–1998 (2023).
5. Phạm Minh Lanh., Trương Công Minh. & Phạm Cẩm Phương. Kết quả điều trị ung thư phổi không tế bào nhỏ giai đoạn IV bằng Pembrolizumab kết hợp hóa trị. VMJ 519, (2022).
6. Wu, Y., Wu, H., Lin, M., Liu, T. & Li, J. Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients. Transl Oncol 15, 101268 (2021).